Clinical trial
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of…
NCT00221624 · University Hospital, Bordeaux, Other · Completed
Key facts
| NCT number | NCT00221624 |
|---|---|
| Title | Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients |
| Official title | Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin |
| Acronym | PEGARI |
| Lead sponsor | University Hospital, Bordeaux, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HCV Infection, Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a, ribavirin, amantadine |
| Enrollment | 131 |
| Start date | Nov 1, 2001 |
| Completion | Apr 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 13, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: